Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| INDP | S-3 | bearish | 6/10 | Indaptus Therapeutics filed an S-3 registration statement to allow selling stockholders (Ting Yang, Lina Deng, and David | Jun 26, 2026 |
| KYMR | 144 | bearish | 6/10 | BVF Partners L.P./IL, an affiliate of a Kymera Therapeutics director, filed a Form 144 on June 26, 2026, signaling inten | Jun 26, 2026 |
| MTNB | 8-K | bearish | 6/10 | Matinas BioPharma received an additional NYSE American deficiency notice for failing Section 1003(a)(ii) (equity below $ | Jun 26, 2026 |
| CAPR | 8-K | neutral | 6/10 | Capricor announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet on July 29, 2026 to | Jun 26, 2026 |
| AKTX | 8-K | neutral | 3/10 | Akari Therapeutics amended its securities purchase agreement to consolidate the second and third closings into a single | Jun 26, 2026 |
| OTLK | 8-K | bullish | 5/10 | Outlook Therapeutics received a letter from Nasdaq on June 26, 2026, confirming that it has regained compliance with the | Jun 26, 2026 |
| VXRT | DEFA14A | neutral | 4/10 | Vaxart filed an updated investor presentation as definitive additional proxy soliciting material, revising details on it | Jun 26, 2026 |
| PAHC | 8-K | neutral | 2/10 | Phibro Animal Health appointed Daniel (Dani) Bendheim as CEO and President effective July 1, 2026, with an employment ag | Jun 26, 2026 |
| VXRT | DEFA14A | neutral | 3/10 | Vaxart filed definitive additional proxy materials (DEFA14A) urging shareholders to vote FOR all six board nominees and | Jun 26, 2026 |
| APGE | DEFA14A | bullish | 6/10 | Apogee Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) in support of its proposed acquisit | Jun 26, 2026 |
| PTCT | CLUSTER | neutral | 2/10 | Three PTCT insiders sold a total of $2.04M in shares over a week, representing only 0.03% of the $7B market cap. The sal | Jun 26, 2026 |
| QUCY | 8-K | bearish | 5/10 | Quantum Cyber N.V. dismissed its auditor Reliant CPA PC and engaged Haskell & White LLP, effective June 22, 2026. The pr | Jun 26, 2026 |
| TYRA | 144 | bearish | 6/10 | Nextech VI Oncology SCSP, a significant VC shareholder, filed a Form 144 to sell 308,379 shares (~$9.5M) after already s | Jun 26, 2026 |
| FF | 8-K | neutral | 2/10 | Director Paul M. Manheim will not stand for re-election at FutureFuel's 2026 annual meeting and will retire from the boa | Jun 26, 2026 |
| IMVT | 144 | neutral | 2/10 | Officer Jay S. Stout filed a Form 144 indicating intent to sell 40,000 shares of Immunovant common stock, valued at appr | Jun 26, 2026 |
| NEUP | PRESS-RELEASE | bullish | 6/10 | Neuphoria Therapeutics confirms it is in preliminary discussions with UK-based Scancell Holdings regarding a potential a | Jun 26, 2026 |
| MNPR | PRESS-RELEASE | bullish | 7/10 | Monopar Therapeutics presented new positive analyses from the Phase 3 FoCus trial of ALXN1840 in Wilson disease at EAN 2 | Jun 26, 2026 |
| INSM | CLUSTER | neutral | 2/10 | Two INSM insiders, including the CEO, sold a combined $1.41M in shares over June 22-25, 2026. The total represents only | Jun 26, 2026 |
| ALGS | 8-K | neutral | 3/10 | Aligos Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting, where stockholders approved an amendm | Jun 26, 2026 |
| IMA | 8-K | neutral | 3/10 | ImageneBio disclosed the resignation of Robert Lally, SVP of Finance and Operations and principal accounting officer, ef | Jun 26, 2026 |
| SEPN | 144 | bearish | 4/10 | Jae B. Kim, an officer of Septerna, Inc., filed a Form 144 on June 26, 2026, indicating intent to sell 94,339 shares of | Jun 26, 2026 |
| SCYX | 8-K | neutral | 3/10 | SCYNEXIS filed an 8-K reporting shareholder approval to increase authorized common stock from 18.75M to 60M shares (post | Jun 26, 2026 |
| BETRF | 6-K | mixed | 6/10 | BetterLife Pharma's 6-K filing for the fiscal Q1 ended April 30, 2026 shows no revenue, a widened net loss of $612,622 ( | Jun 26, 2026 |
| HCWB | 8-K | neutral | 4/10 | HCW Biologics announced a 1-for-6 reverse stock split effective June 30, 2026, to ensure compliance with Nasdaq's minimu | Jun 26, 2026 |
| BAK | 6-K | mixed | 5/10 | Braskem obtained a 60-day court-ordered stay of creditor enforcement actions to facilitate financial mediation, providin | Jun 26, 2026 |
| RDY | 6-K | bearish | 5/10 | Dr. Reddy's received a Form 483 with seven observations from the USFDA following a Pre-License Inspection at its biologi | Jun 26, 2026 |
| KALA | EFFECT | bearish | 7/10 | KALA BIO's shelf registration (File No. 333-295667) became effective on June 25, 2026, allowing the company to conduct o | Jun 26, 2026 |
| TVGN | EFFECT | bearish | 5/10 | Tevogen Bio's S-3 shelf registration (File No. 333-296760) became effective on June 25, 2026, enabling the resale of up | Jun 26, 2026 |
| PRQR | 6-K | bearish | 6/10 | ProQR priced a $50.0 million underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, a | Jun 26, 2026 |
| EXOZ | 8-K | neutral | 4/10 | ExoZymes announced a $2,028,518 NIH SBIR Phase IIB grant to advance cannabinoid analogs for drug discovery. The two-year | Jun 26, 2026 |